Codexis announces agreement to manufacture 50 g siRNA

Codexis (CDXS) announced it has entered into an agreement with “an innovator pharmaceutical company” to manufacture 50 grams of small interfering RNA using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to support its partner’s preclinical program. “We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity,” said Alison Moore, President and Chief Executive Officer of Codexis. “Engagements like this illustrate our path to growth as we continue to expand partnerships and position the platform for potential commercial-scale applications.”